Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Azthreonam activity against gram-negative bacilli.

D A Bremner

    Chemotherapy
    |January 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Aztreonam, a monocyclic beta-lactam antibiotic, demonstrated potent in vitro activity against gram-negative bacilli. It was comparable or superior to third-generation cephalosporins against most Enterobacteriaceae, except Klebsiella.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Surveillance for antimicrobial resistance in enterococci.

    The New Zealand medical journal·1997
    Same author

    The in-vitro activity of biapanem against 964 clinical isolates of aerobic bacteria.

    The Journal of antimicrobial chemotherapy·1995
    Same author

    Cryptococcal meningitis in Auckland 1969-89.

    The New Zealand medical journal·1991
    Same author

    Plasma and dialysate levels of pefloxacin and its metabolites in CAPD patients with peritonitis.

    The Journal of antimicrobial chemotherapy·1990
    Same author

    Clinically significant Streptococcus anginosus (Streptococcus milleri) infections: a review of 186 cases.

    The New Zealand medical journal·1988
    Same author

    In-vitro activity of fleroxacin compared with three other quinolones.

    The Journal of antimicrobial chemotherapy·1988

    Area of Science:

    • Microbiology
    • Pharmacology
    • Infectious Diseases

    Background:

    • Beta-lactam antibiotics are crucial in treating bacterial infections.
    • Gram-negative bacilli pose significant therapeutic challenges due to resistance mechanisms.
    • Aztreonam is a unique monocyclic beta-lactam with a distinct spectrum of activity.

    Purpose of the Study:

    • To evaluate the in vitro antibacterial activity of aztreonam.
    • To compare aztreonam's efficacy against third-generation cephalosporins and other beta-lactams.
    • To assess activity against a diverse panel of clinical isolates of gram-negative bacilli.

    Main Methods:

    • In vitro susceptibility testing.
    • Comparison of azthreonam with ampicillin, cephalothin, cefuroxime, cefotaxime, cefoperazone, lamoxactam, ceftazidime, and N-formimidoyl thienamycin.

    Related Experiment Videos

  • Testing against 249 clinical isolates of gram-negative bacilli.

    • Main Results:

    • Aztreonam exhibited potent activity against most Enterobacteriaceae, often exceeding that of third-generation cephalosporins.
    • Activity against Klebsiella was variable, with aztreonam being more active than cefoperazone but less so than other third-generation agents.
    • Aztreonam demonstrated equal activity to ceftazidime and piperacillin against Pseudomonas aeruginosa.

    Conclusions:

    • Aztreonam is a highly active monocyclic beta-lactam antibiotic against a broad range of gram-negative bacilli.
    • Its activity profile offers a valuable alternative, particularly against certain challenging pathogens.
    • Further clinical evaluation is warranted to establish its therapeutic role.